Member Info for LordSnooty

I must say this latest offering from Chuckles of Changi scrapes the proverbial.

It is true, even toffs like myself live in straitened circumstances these days. Philanthropist that I am, and much as I try to protect my serfs from the chill winds of misfortune, I have had to reduce their daily potage by half a cup, and the ration of small beer that I generously - though foolhardily - allowed them last year, has had to be withdrawn. Nary a complaint from those stout peasants do I hear, though I am curious as to how a brick with my name on it found its way through the 13th century stained glass altar window in Chapel Snooty , the family seat of worship, recently. Complaints from that direction hear I none, but this is amply compensated for by the hourly whinings of Her Ladyship. Rashly I promised her the Earth some months ago, on the strength of covert intelligence gleaned from the Puce Predictor. Little was I to know at that time that the design of the old Mark I was fundamentally flawed. Such ignorance has cost me many sleepless, harangue-filled nights since. However, as I posted some weeks ago, the new, improved Predictor, Mark II is now fully functional and just the other day leaned strongly towards events of Hellenic proportions taking place shortly on the XEN front. Armed with this new data I have managed to mollify the Beast in my Bed somewhat, to the extent that I can currently anticipate at least three hours sleep a night.

Agreed about Russia and India but from the tone of the Finals, seems US listing could be soon. I haven't given up hope of another RNS about that before the CC, to put some meat on the bone.

Agreed about Russia and Indian, but from the tone of the Finals, s to put some meat on the bone.eems US listing could be soon. I haven't given up hope of another RNS about that before the CC to put some meat on the bone.

Xenetic Biosciences plc (LSE: XEN.L), a bio-pharmaceutical company specialising in the development of high-value differentiated biological products, vaccines and novel cancer drugs, announces that it will host an analyst and investor conference call at 14:00 BST on Thursday 20 June 2013. The conference call will be hosted by Xenetic's CEO Scott Maguire, followed by a Q&A session. No new operational or financial information will be disclosed. The conference call will commence at 14.00 BST and is expected to close at 14:30 BST. To join the call, participants should dial: · United Kingdom: 0800 368 0649 · United Kingdom (Local): 020 3059 8125 · All Other Locations: +44 20 3059 8125 When joining the call, participants must quote the password 'Sciences' to the Operator, in order to gain access to the conference.

old and new! The time is fast approaching when you must decide whether or not to make that final top-up. I myself have tucked away a few extra nuggets these past few days. Her Ladyship fully approves, and in fact has pawned her Edwardian diamanté hat pin set in order buy more shares to secrete in her copious girdle Remember, we are New World bound, where big hats are worn. Such bargains as these will not last when Elmer and Hiram sniff a bargain!

in the case of XEN, and since nothing ever happens to the share price, one will likely hold one's shares until one expires, by which time HMRC will owe the Snooty estate several millions. Her Ladyship is delighted at your news.

Jimmy does not know where you live, but he knows where you will die.

Jimmy also hides his bushels under his tights.

that Jimmy can kill two stones with one bird.

that Jimmy's calendar goes straight from March 31st to April 2nd: nobody fools with Jimmy.

Enjoys Diverse Portfolio, Reckons Broker By Giles Gwinnett June 07 2013, 11:03am With its diverse product portfolio, Xenetic Biosciences (LON:XEN) has multiple opportunities to create value, says broker N+1 Singer, after the firm posted its 2012 numbers. Key drivers in the short term will be the start of phase II trials for ErepoXen in Australia, for chronic anaemia, during this summer and the phase II data from OncoHist, for cancer, says the broker. Thursday's results statement also updated on the firm's plan for a corporate move to the USA, saying that it plans to open new laboratory facilities in Massachusetts in September or October this year. "It also intends to undertake a pre-marketing programme in the US to build awareness of the investment case ahead of a potential US listing," notes N+1 singer analyst Sheena Berry. The company told investors yesterday: "The long term benefits of being a US-centric organisation will become apparent as a result of US markets conferring significantly greater value on enterprises such as Xenetic with its broad technology offering and vibrant proprietary drug pipeline." Last month, Xenetic said it had completed the phase I, safety trial for multiple sclerosis (MS) treatment MyeloXen, without any adverse effects, and its Russian partner Pharmsynthez, has now started treating patients to establish dosing levels. A day earlier, it dosed the first patient in its phase III trial for ErepoXen. As at Dec 31 last year, the firm's net asset value stood at £14.5 mln compared to £10.9 mln in 2011. The total pre-tax loss for the year was £3.3 mln (2011 loss: £2.8 mln). Analyst Berry summed up: "Xenetic’s diverse product portfolio provides the company with multiple opportunities for creation of shareholder value." As well as the short term drivers, the analyst said: " We are also looking forward to the result of mechanism of action studies on OncoHist being released this year and more details on the company’s transition to the US." Shares were unchanged today at 6.75p.

Xenetic Biosciences sees benefits of becoming US-centric organisation By Proactive Investors June 06 2013, 5:22pm Looking ahead, the firm will begin its first western clinical trial in June or July this year via a phase II clinical trial in Australia for ErepoXen, it added After positive developments in the year gone, Xenetic Biosciences (LON:XEN) is moving towards its rebirth as a specialty drug developer working with partners in Russia, India and the United States. Releasing its 2012 results, the firm also updates on its corporate transition to the US, saying its offices in Massachusetts are expected to be available in September or October, 2013. "This will allow the drug development work of the group to be greatly accelerated and also, upon the completion of a fundraising, the advancement of the self-determination of the group's future growth. "The long term benefits of being a US-centric organisation will become apparent as a result of US markets conferring significantly greater value on enterprises such as Xenetic with its broad technology offering and vibrant proprietary drug pipeline." Among the highlights following the results period, in May the firm completed the Phase I, safety trial for its multiple sclerosis (MS) treatment MyeloXen and is now treating patients to establish dosing level. Meanwhile, the phase III trial for ErepoXen, for treating anaemia, began in Russia last month. Looking ahead, the firm will begin its first western clinical trial in June or July this year via a phase II clinical trial in Australia for ErepoXen, it added. As at Dec 31 last year, the firm's net asset value stood at £14.5 mln compared to £10.9 mln in 2011. The total pre-tax loss for the year was £3.3 mln (2011 loss: £2.8 mln). hxxp://www.proactiveinvestors.co.uk/companies/news/57739/xenetic-biosciences-sees-benefits-of-becoming-us-centric-organisation--57739.html

Let's keep this in perspective: £5m+ still in the bank, $1m to come from Baxter, almost certainly more to come from there in milestone payments when Ph I of Factor VIII gets under way, a possible licensing out of PSA-EPO in the next year to eighteen months, US listing which without doubt will lead to an increase in sp, possibly an incremental one. Yes, to fund such an ambitious trial programme of multiple candidates will require extra funds, but a) not imminently and b) not without concomitant progress in the pipeline, leading to a much improved share price. All in Snooty's very learned opinion.

they were clearly worried about your reaction if they published a morning RNS. Either that or perhaps there's another to come and they wanted to keep them separate.

multiple candidates in development, one already in Ph III, de-risked strategy , money in the bank, payment from Baxter due and more stage payments to come.

do not be seduced by the honeyed words of the Singapore Swindler; he promises much but delivers little. Follow instead the True Path laid before you by Snooty. You know it makes cents!

and the darling buds of May have given way to full leaf in the Snootoretum. June again, and it is time for Marshall Snooty to rally the troops once more. Up and over, I say, don't shoot until you see the whites of their eyes, then give 'em both barrels! Now is not the time to be pussyfooted, lily-livered. Now is the moment to press home our advantage! We have three, fully-patented, world-beating, gold-plated!, diamond-encrusted, fully funded technologies. What do we care that the risk-averse shrinking violets are too afraid to buy our magnificent stock, brave Xenophiles? We are New World bound, where opportunities drip like nectar from the trees. Have faith, dear People of the Xen, remember - semper fidelis; hic, haic, hoc; ars longa, vita brevis; per ardua ad astra; amo, amas, amat; veni, vidi, vinci!

The first question is impossible to answer. I myself see PSA-EPO entering Australian trials as a watershed, for reasons I've already stated. Unfortunately, what the market makes of this is another matter, and not something XEN can influence much, beyond a decent PR offensive explaining its significance. With market indifference in the UK to junior pharma at the moment, the signs are not too encouraging, in which case perhaps we should be pinning our hopes on the much-discussed listing in the US, where the pharma sector is booming, happening soon. But of course we don't have a timeline for that, for legal reasons among others. In answer to the second question - no, it's impossible to know the details, in terms of how much we'll earn, when it will take place, etc, of any potential outlicence. I'm sure you can infer from the lack of information we get from our Baxter deal, which has been running for several years now, that such tie-ups with Big Pharma are very bound up with commercial confidentiality. I only know that there IS interest in our product - I'd like to think significant interest.

PSA-EPO Ph II start in Oz is more important since it will, with luck, lead to a deal with a Pharma before the expense of Ph III, meaning our second revenue source after Baxter, and much more advanced towards the market and royalties. I expect that start soon now. As for Big Pharma deal/US listing, impossible to say beyond reading the signs - for example the independently-instigated listing on OTC market last month. Patience will get us there.